Lyra Therapeutics appoints Jason Cavalier as CFO; R. Don Elsey to transition out

Lyra Therapeutics, Inc.

Jason Cavalier appointed CFO, Treasurer, Secretary, principal financial and accounting officer effective Sept 12, 2021.
Cavalier receives $400K base salary, 40% target bonus, and option for 104,000 shares vesting over 4 years.
Outgoing CFO R. Don Elsey will work full-time through Oct 6, then part-time until Dec 31, 2021 under a transition agreement.
Elsey retains $375K base salary (prorated during part-time) and eligible for 2021 bonus up to 40% of actual salary earned.
Cavalier also receives up to $6,250/month for travel between New York and Watertown, plus corporate apartment and tax gross-up.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

R. Don Elsey

Chief Financial Officer

LYRA · Lyra Therapeutics, Inc.

Effective: 2021-09-12
Successor: Jason Cavalier
Filed: September 15, 2021, 7:59 PM ET

Mr. Cavalier was also designated as the Company’s principal financial officer and principal accounting officer, and succeeds R. Don Elsey as Chief Financial Officer and principal financial officer and principal accounting officer.

Appointed

Jason Cavalier

Chief Financial Officer, Treasurer and Secretary

LYRA · Lyra Therapeutics, Inc.

Effective: 2021-09-12
Filed: September 15, 2021, 7:59 PM ET

On September 12, 2021, the Board of Directors (the “Board”) of Lyra Therapeutics, Inc. (the “Company”) appointed Jason Cavalier as Chief Financial Officer, Treasurer and Secretary of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

R. Don Elsey departed as Chief Financial Officer at Lyra Therapeutics, Inc..

Action: succeeded
Role: Chief Financial Officer

Exact text from the filing

Mr. Cavalier was also designated as the Company’s principal financial officer and principal accounting officer, and succeeds R. Don Elsey as Chief Financial Officer and principal financial officer and principal accounting officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Jason Cavalier was appointed as Chief Financial Officer, Treasurer and Secretary at Lyra Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer, Treasurer and Secretary

Exact text from the filing

On September 12, 2021, the Board of Directors (the “Board”) of Lyra Therapeutics, Inc. (the “Company”) appointed Jason Cavalier as Chief Financial Officer, Treasurer and Secretary of the Company.

View on SEC.gov

Lyra Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001564590-21-048046

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.